why choose us

First received: December 30, 2022

Clinical Trial: A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Solid Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Brief Summary: To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.

Read more